DSIP (Delta Sleep-Inducing Peptide): What the Research Literature Covers

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

This article covers delta sleep-inducing peptide (DSIP): the 1977 rabbit experiments that gave it its name, the nonapeptide's chemistry and instability, why replication has been inconsistent for nearly fifty years, and what modern papers report. The name is a hypothesis from 1977, not an established function, and the article reads it that way.

DSIP is a nine-residue peptide named for an EEG effect in rabbits

Delta sleep-inducing peptide is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with a molecular weight of about 849 daltons and the international nonproprietary name emideltide. It was isolated by Schoenenberger and Monnier's group in Basel and characterized in a 1977 Proceedings of the National Academy of Sciences paper. The isolation program is unusual and worth describing because it explains the name. From 1963 onward, Monnier's laboratory kept donor rabbits asleep by electrical stimulation of the thalamus, dialyzed blood from the cerebral venous sinus, and introduced the dialysate into the brain ventricles of recipient rabbits, whose EEG then showed more slow-wave (delta) activity. Schoenenberger's 1984 review in European Neurology recounts that it took until 1977 to purify the responsible fraction to a single nonapeptide.

The 1977 paper tested the hypothesis more carefully than many later studies did. The authors synthesized the nonapeptide, five fragments (residues 1 to 8, 2 to 9, 2 to 8, 1 to 4, and 5 to 9), two analogs with substituted residues, and an unrelated tripeptide, and delivered each into the cerebral ventricles of rabbits under double-blind conditions, 58 animals in all, with EEG recorded from neocortex and hippocampus and analyzed by fast Fourier transform. Only the intact nonapeptide produced a significant increase in delta and spindle activity. A companion paper by Monnier, Dudler, and colleagues in Experientia the same year compared the original isolate with the synthetic peptide and reported matching properties.

Note what the finding was: a change in EEG spectral power after direct delivery into the brain of a rabbit. "Sleep-inducing" in the name was an inference about what that EEG pattern meant.

Replication has been inconsistent since the beginning

Doubts appeared within a few years. Kovalzon and Tsibulsky published a 1983 paper in Neuroscience and Behavioral Physiology whose title asks "Does synthetic delta sleep-inducing peptide possess hypnogenic properties?" Obál, Kovalzon, and colleagues reported in a 1986 Pharmacology Biochemistry and Behavior paper that in rats recorded over a full dark and light period, DSIP itself did not increase sleep, whereas two analogs with a D-tryptophan or D-tyrosine at position 1 did, and a shortened D-Trp analog actually increased wakefulness. Their explanation was that DSIP is degraded too quickly to act, and that the active species in earlier work might have been something more stable.

Graf and Kastin's reviews in Neuroscience and Biobehavioral Reviews (1984) and Peptides (1986) catalog the positive and negative reports and note a recurring feature: a U-shaped activity curve, with effects appearing in a narrow middle range and vanishing above and below it. Schoenenberger's own 1984 review calls the response "parabolic". A U-shaped curve can be real pharmacology, but it also makes negative results easy to explain away and positive ones hard to reproduce, which is part of why the field never settled.

Kovalzon and Strekalova's 2006 review in the Journal of Neurochemistry, titled "DSIP: a still unresolved riddle", is the clearest modern statement. They note that no gene encoding DSIP has ever been found, no precursor protein has been identified, and no receptor has been characterized, so the peptide has no established biosynthetic origin. They also note that DSIP-like immunoreactivity in the brain is concentrated in hypothalamic neurosecretory nuclei that are not sleep centers, and that in their own rabbit and rat work certain synthetic analogs, but not DSIP itself, increased slow-wave sleep. Their proposal is that an as-yet-unidentified DSIP-like peptide may account for both the immunoreactivity and the activity.

Human studies: small, mixed, and now old

The human EEG literature is small and comes mostly from one Swiss group. Schneider-Helmert, Graf, and Schoenenberger reported in a 1981 Lancet letter that the synthetic peptide improved sleep in a small group of people with insomnia, and Schneider-Helmert's 1987 paper in European Neurology described 14 middle-aged adults with chronic insomnia studied under placebo-controlled, double-blind conditions over seven nights, with reported improvement in polysomnographic sleep efficiency and daytime performance. Both reports are short, and neither has been replicated at scale.

The one fully independent double-blind study came from Bes, Hofman, and colleagues in a 1992 paper in Neuropsychobiology. Sixteen adults with chronic insomnia were studied for five consecutive laboratory nights in a matched-pairs parallel-group design. Sleep efficiency and sleep latency were statistically better after the peptide than after placebo, but the authors judged the effects weak, noted they could partly reflect a chance change in the placebo group, found no change in subjective sleep quality, and concluded that the peptide was unlikely to offer a major benefit in that setting. Späth-Schwalbe and colleagues' 1995 study in Psychoneuroendocrinology tested the separate claim that DSIP inhibits corticotropin release, and found no effect on ACTH or cortisol responses to corticotropin-releasing hormone or to a meal in healthy men.

A 2009 study by Pomfrett and colleagues in the European Journal of Anaesthesiology went in an unexpected direction. In 24 women under isoflurane anesthesia, DSIP increased heart rate, decreased heart-rate variability, and, "paradoxically", reduced EEG delta rhythm and raised the bispectral index, which the authors read as a lightening rather than a deepening of anesthetic depth.

Chemistry: a flexible, rapidly degraded nonapeptide that crosses membranes

DSIP's structure has been studied by NMR. Gray and colleagues' 1994 paper in Biochemistry used one- and two-dimensional NMR, circular dichroism, Fourier-transform infrared spectroscopy, and fluorescence, and concluded that the peptide exists in a dynamic equilibrium between unordered and folded forms, with residues 2 to 5 and 6 to 9 tending to form type I beta-turns in water (about 40% beta-turn population by infrared) and a more ordered helix-like fold in 40% trifluoroethanol. The authors' stated motive was to model how a charged, hydrophilic peptide crosses the blood-brain barrier.

The membrane-crossing claim itself comes from Kastin's laboratory. Banks, Kastin, and Coy reported in a 1982 Pharmacology Biochemistry and Behavior paper that DSIP and two analogs given into the bloodstream of anesthetized dogs appeared in cerebrospinal fluid, that the peptide is reversibly bound to a large plasma protein, and that free peptide appears to be the species that crosses.

Stability is the peptide's defining practical problem. Graf, Saegesser, and Schoenenberger reported in a 1987 Peptides paper that DSIP incubated in human or rat blood released a product co-eluting with free tryptophan, meaning the N-terminal residue is clipped quickly, with the rate depending on temperature, time, and species. Schoenenberger's 1984 review gives a 15-minute half-life for tryptophan removal by brain slices. A phosphorylated analog with phosphoserine at position 7 (P-DSIP) was synthesized to slow this and was reported to be more potent and longer-lived; Graf's 1987 paper found the labeled phosphorylated analog degraded more slowly but also formed non-specific complexes with plasma components. The aliquot and oxidation article covers the general problem of tryptophan oxidation in stored solutions, which applies here.

DSIP-like immunoreactivity: real signal, uncertain source

Antibodies raised against DSIP detect something in many tissues. Feldman and Kastin's 1984 immunocytochemical study in Neuroscience mapped DSIP-immunoreactive neurons through the rat forebrain and brainstem and commented that this distribution suggested involvement in arousal, locomotor, auditory, and sensory systems rather than sleep specifically. Graf, Hunter, and Kastin found DSIP-like material in human milk in a 1984 Journal of Clinical Endocrinology and Metabolism paper.

Friedman and colleagues measured plasma DSIP-like immunoreactivity every 30 minutes for 24 hours in 12 volunteers with simultaneous polysomnography, in a 1994 Journal of Clinical Endocrinology and Metabolism paper. They found a clear diurnal rhythm, peaking at 15:00 and lowest at 01:00, that tracked body temperature. Levels were lower during REM and slow-wave sleep than during wakefulness and did not rise before or during slow-wave episodes. The authors concluded that circulating DSIP-like material, if anything, accompanies suppression of delta sleep, which is the opposite of what the name predicts. Because no gene exists to confirm what these antibodies recognize, "DSIP-like immunoreactivity" should be read literally.

What recent papers report, and the regulatory position

Work since 2000 has drifted away from sleep. Umriukhin's 2002 paper in the Bulletin of Experimental Biology and Medicine used microiontophoresis in rat brain and reported that prior application of DSIP blocked the excitatory effect of glutamate on neurons in hippocampus, thalamus, hypothalamus, and cortex. Stanojlović and colleagues' 2005 paper in Seizure reported that DSIP and a tetrapeptide analog reduced the severity of metaphit-provoked audiogenic seizures in rats. Tukhovskaya and colleagues' 2021 paper in Molecules used a rat middle-cerebral-artery occlusion model and reported faster recovery of rotarod performance in animals given DSIP nasally over eight days, with no significant difference in infarct volume. None of these is a replication of the 1977 EEG result.

DSIP is not an approved drug in the United States or, as far as the indexed literature shows, anywhere else. The FDA status reference table records its position, including the 2026 advisory-committee review of its nomination for the compounding bulk-substances list. For a research certificate, the relevant chemistry is simple: nine residues, a single N-terminal tryptophan that gives the peptide its 280 nm absorbance and its main oxidation and cleavage liability, a calculated mass near 849 daltons, and an acidic net charge from the aspartate and glutamate. US Prime Peptides posts the lot-matched certificate for DSIP 10 mg on its product page, and the Sleep Research Blend liquid spray is documented with a per-bottle labeled mass for each component, as described in the liquid spray formulation article.

Frequently Asked Questions

What is DSIP and where did it come from?

DSIP is a nine-residue peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated by Schoenenberger and Monnier in Basel from the cerebral venous blood of rabbits kept asleep by thalamic stimulation. The 1977 PNAS paper showed that the synthetic nonapeptide, delivered into rabbit brain ventricles, increased delta and spindle EEG activity.

Has the sleep effect of DSIP been replicated?

Inconsistently. Some rabbit and human reports from the original group were positive; Obál and Kovalzon found no sleep increase from DSIP itself in rats, the one independent double-blind human study (Bes et al., 1992) found only weak effects, and a 2006 review called the question "a still unresolved riddle". No gene, precursor, or receptor for DSIP has been identified.

Why is DSIP unstable in solution?

The N-terminal tryptophan is removed rapidly by peptidases; Graf and colleagues (1987) saw free tryptophan appear when DSIP was incubated in blood, and brain tissue was reported to clip it with a 15-minute half-life. Tryptophan is also the residue most prone to oxidation during storage. A phosphorylated analog (P-DSIP) was made to slow degradation.

Is DSIP an approved drug?

No. DSIP (INN emideltide) is not an approved drug in the United States, and no marketing approval elsewhere appears in the literature. A research-grade vial is supplied for in vitro laboratory use only.

Citations

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74:1282-1286. PMID 265572
2. Monnier M, Dudler L, Gächter R, et al. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33:548-552. PMID 862769
3. Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984;23:321-345. PMID 6548966
4. Koval'zon VM, Tsibul'skii VL. Does synthetic delta sleep-inducing peptide possess hypnogenic properties? Neurosci Behav Physiol. 1983;13:243-244. PMID 6689203
5. Obál F Jr, Kovalzon VM, Kalikhevich VN, et al. Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacol Biochem Behav. 1986;24:889-894. PMID 3754970
6. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8:83-93. PMID 6145137
7. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7:1165-1187. PMID 3550726
8. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97:303-309. PMID 16539679
9. Schneider-Helmert D, Graf M, Schoenenberger GA. Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. Lancet. 1981;1:1256-1257. PMID 6112579
10. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27:120-129. PMID 3622582
11. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26:193-197. PMID 1299794
12. Späth-Schwalbe E, Schäfer A, Uthgenannt D, et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995;20:231-237. PMID 7777652
13. Pomfrett CJ, Dolling S, Anders NR, et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009;26:128-134. PMID 19142086
14. Gray RA, Vander Velde DG, Burke CJ, et al. Delta-sleep-inducing peptide: solution conformational studies of a membrane-permeable peptide. Biochemistry. 1994;33:1323-1331. PMID 8312250
15. Banks WA, Kastin AJ, Coy DH. Delta sleep-inducing peptide crosses the blood-brain-barrier in dogs: some correlations with protein binding. Pharmacol Biochem Behav. 1982;17:1009-1014. PMID 6897451
16. Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987;8:599-603. PMID 3628078
17. Feldman SC, Kastin AJ. Localization of neurons containing immunoreactive delta sleep-inducing peptide in the rat brain: an immunocytochemical study. Neuroscience. 1984;11:303-317. PMID 6371579
18. Graf MV, Hunter CA, Kastin AJ. Presence of delta-sleep-inducing peptide-like material in human milk. J Clin Endocrinol Metab. 1984;59:127-132. PMID 6547144
19. Friedman TC, Garcia-Borreguero D, Hardwick D, et al. Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep. J Clin Endocrinol Metab. 1994;78:1085-1089. PMID 8175965
20. Umriukhin PE. Delta sleep-inducing peptide blocks excitatory effects of glutamate on rat brain neurons. Bull Exp Biol Med. 2002;134:5-7. PMID 12459854
21. Stanojlović OP, Zivanović DP, Mirković SD, Jovanović A. Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats. Seizure. 2005;14:240-247. PMID 15911358
22. Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke. Molecules. 2021;26:5173. PMID 34500605

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.